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Background:  Catheter  ablation  is  now  an alternative  approach  to antiarrhythmic  drug  therapy  for  patients
with  symptomatic  atrial  ﬁbrillation  (AF). We  focused  on younger  patients  in  whom  the  prevalence  of  AF
is low,  and  we  sought  clinical  factors  associated  with  unsuccessful  ablation  outcomes.
Methods and results:  Among  1983  consecutive  symptomatic  patients  who  underwent  AF ablation  proce-
dures,  95  patients  (4.8%),  age  ≤  40  years,  were  prospectively  included.  Of them,  64 had  paroxysmal  AF,
and  the  remaining  31  had  persistent  AF.  All  patients  underwent  pulmonary  vein  isolation  and  cavotricus-
pid  isthmus  ablation.  When  AF recurred,  redo  ablations  were  performed  if the patients  desired.  The  mean
number  of  ablation  procedures  was  1.3 ±  0.6  times  per  patient.  During  the  follow-up  of 40  [27.8–49.6]
months,  sinus  rhythm  was  maintained  in  86  patients  (90.5%)  without  any  antiarrhythmic  drugs,  butounger patients
ody mass index
utcome
not  in  the remaining  9  patients  (9.5%).  Low  body  mass  index  (BMI)  and  persistent  AF were  associated
with  unsuccessful  ablation  procedures.  In multivariate  logistic  regression  analysis,  a low  BMI  had  the
most  signiﬁcant  value,  with  an  odds  ratio  of 7.33  (p = 0.022).  The  receiver  operating  characteristic  curve
demonstrated  a BMI  cut point  of  22.1  kg/m2, with  an area  under  the  curve  of  0.773.
Conclusion:  In  symptomatic  younger  AF  patients,  a low  BMI  was  an  independent  clinical  factor  for  unsuc-
mes.
3  Japcessful  AF  ablation  outco
© 201
ntroduction
Over the past decade, many centers have reported high success
ates and few complications associated with catheter ablation in
ymptomatic patients with drug-refractory atrial ﬁbrillation (AF)
1–6]. Recent practice guidelines recommend catheter ablation as
n alternative approach to antiarrhythmic drug (AAD) therapy for
atients with symptomatic AF [7,8]. The stage of AF (i.e. paroxys-
al, persistent, or permanent), the size of the left atrium (LA), and
he presence and severity of an underlying cardiac disease have
een deﬁned as clinical factors for a successful catheter ablation
rocedure [7,8]. These data are derived from the general popula-
ion with AF. As is well known, AF mainly occurs in elderly patients.
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Therefore, most clinical data relevant to AF are derived from this
patient population.
The purpose of this study was to evaluate the clinical factors
for an unsuccessful ablation outcome in symptomatic younger AF
patients who generally have a lower prevalence of AF than elderly
patients.
Methods
Study population
Of 1983 consecutive patients who  underwent a catheter abla-
tion procedure for eliminating symptomatic AF at our institutes
between February 2007 and September 2010, 95 patients (4.8%)
who were ≤40 years old (36 ± 4 years, 85 men) were included
in this study. Among them, 64 patients (67%) had paroxysmal
AF and 31 patients had persistent AF (33%). Of the patients with
persistent AF, 14 (45%) had long-standing persistent AF. The def-
initions of paroxysmal, persistent, and long-standing persistent
AF followed the practice guidelines for the management of AF,
which are according to the European Heart Rhythm Association
or the American College of Cardiology Foundation/American Heart
vier Ltd. All rights reserved.
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ssociation/Heart Rhythm Society [7,8]. Concerning the underly-
ng cardiac diseases, 6 patients (6%) had structural heart disease
ssociated with cardiomyopathy (3 dilated cardiomyopathy and
 hypertrophic cardiomyopathy) and 2 patients (2%) had post-
perative congenital heart disease. Fourteen patients (15%) had
ypertension.
All patients gave their written informed consent for the study
rotocol, which was approved by the institutional review boards.
reparation for catheter ablation
All AADs were discontinued 7 days before the ablation session
nd were effectively anticoagulated for >1 month. Transesophageal
chocardiography was performed to exclude any atrial thrombi
efore the ablation. From February 2007 to July 2009, warfarin was
iscontinued 3–5 days before the AF ablation session, and heparin
ridging was performed during the periprocedural period until the
nternational ratio returned to 2–3 after the resumption of war-
arin. After August 2009, warfarin was continued throughout the
eriprocedural period.
lectrophysiological study before the ablation procedure
The surface electrocardiograms (ECGs) and bipolar intracar-
iac electrograms were continuously monitored and stored on
 computer-based digital recording system [Cardiolab system
Prucka Engineering, Houston, TX, USA) or LabSystem PRO (Bard
lectrophysiology, Lowell, MA,  USA)].
The bipolar electrograms were ﬁltered from 30 to 500 Hz. A 7-
r 20-pole or 14-pole 2-site mapping catheter (Irvine Biomedical,
rvine, CA, USA) was inserted through the right jugular vein and
ositioned in the coronary sinus for pacing, recording, and internal
ardioversion. The electrophysiological study was performed under
onscious sedation with propofol or dexmedetomidine.
atheter ablation procedure
All patients underwent pulmonary vein isolation (PVI). In this
tudy, sinus rhythm was maintained in 60 patients (63.2%) at the
eginning of the procedure, but the remaining 35 patients (36.8%)
eveloped AF. When the patients were in sustained AF before the
rocedure, we certainly performed a cardioversion before the AF
blation. However, when AF recurred after the cardioversion, we
erformed the PVI during the AF. The procedure was  performed
n the postabsorptive state under conscious sedation. The PVI
pproach performed at our institutes has been previously described
n detail [9,10]. Brieﬂy, after a single transseptal puncture, 3 long
-Fr sheaths (SL0; AF Division, St. Jude Medical, St. Paul, MN,  USA)
ere introduced into the LA. A 5000 IU intravenous bolus of heparin
as administered after the transseptal puncture, with a continu-
us infusion of 1000 IU/h to maintain an activated clotting time of
00–350 s. Two 5-Fr circular mapping catheters (Lasso; Biosense
ebster, Diamond Bar, CA, USA) through 2 long sheaths were
laced in the superior and inferior pulmonary veins (PVs), respec-
ively.
The left- and right-sided ipsilateral PVs were circumferen-
ially and extensively ablated during an intravenous isoproterenol
nfusion (1 mg/min) under ﬂuoroscopic and electrophysiologic
uidance. Radiofrequency current was delivered with an 8-mm-tip
onirrigated ablation catheter (Japan Lifeline, Tokyo, Japan) or a
.5-mm irrigated tip ablation catheter (Biosense Webster) through
nother long sheath. The end point of the ablation was  the elimi-
ation of all PV potentials.
After completing PVI, cavotricuspid isthmus (CTI) ablation was
lso performed to create a bidirectional conduction block. We  cer-
ainly perform intravenous injections of ATP in all cases after theology 63 (2014) 438–443 439
PVI except for in patients with bronchial asthma. Further, an incre-
mental isoproterenol infusion (starting at 5 g, and increasing it up
to 10 g, and 20 g/min for 2 min) was also given before and after
the PVI, and was  limited only by patient intolerance, hypotension,
or the onset of AF. Fundamentally, we did not use any navigation
systems such as CARTO (Biosense Webster) and EnSite (St. Jude
Medical) in the ﬁrst session. If frequent atrial premature contrac-
tions not generated from PVs were present, focal ablation targeting
non-PV foci was  added. When AF recurred, a redo PVI and linear
ablation (the left atrial roof, inferior line, or mitral isthmus line)
or continuous fractionated atrial electrogram (CFAE) ablation were
performed if the patients desired to eliminate their AF. In such
cases, we occasionally used electro-anatomical mapping technique
(CARTO) for eliminating AF.
Postablation follow-up
Patients were followed up in an outpatient clinic at 1, 3, 6, and
12 months after the procedure, then further followed up either in
an outpatient clinic or contacted by telephone every 12 months. AF
recurrence was assessed on the basis of the patient’s symptoms
in conjunction with serial 12-lead ECGs performed during each
outpatient clinic visit, and 24-h Holter ECGs were performed at
3, 6, and 12 months. Patients who had symptoms were provided a
portable ECG monitor (Omron, Kyoto, Japan) to monitor events for
the duration of our study.
Discovery of paroxysmal or persistent episodes of AF/atrial
tachycardia (AT) continuous for ≥30 s after the 2-month blank-
ing period were considered a recurrence of tachyarrhythmia, and
a repeat procedure was performed if the patients desired. Free-
dom from AF was  deﬁned as no detectable AF/AT episodes on ECG
modalities after the ﬁnal procedure.
After 3–6 months, in the absence of any AF, anticoagulant
treatment was  discontinued unless other major risk factors were
present. AADs were not prescribed for patients with paroxysmal AF,
but were prescribed for 3 months following the ablation in patients
with persistent AF.
Statistical analysis
Continuous variables were expressed as mean ± standard devi-
ation or median (25–75%) value. Comparisons between patients
with successful and those with unsuccessful ablation outcomes
were performed using unpaired t test, Fisher’s exact test, or
Mann–Whitney test. Multivariate logistic regression analysis was
constructed to assess the most signiﬁcant indices as clinical fac-
tors for an unsuccessful ablation outcome in younger AF patients.
Parameters that had a correlation (p < 0.2) with unsuccessful abla-
tion outcomes in the univariate analysis were included in the
multivariate analysis. If two  parameters exhibited collinearity, one
of the two parameters was  excluded in the multivariate analysis.
A p-value of <0.05 (2-tailed) was considered to indicate statisti-
cal signiﬁcance. A receiver operating characteristic (ROC) curve for
the body mass index (BMI) was  created with the area under the
curve (AUC) to determine the cut point for an unsuccessful ablation
procedure.
All statistical analyses were performed using a commercially
available computer software (SPSS, version 18.0, Chicago, IL, USA).
Results
Patient characteristicsThe characteristics of the symptomatic younger AF patients in
this study are shown in Table 1. The mean BMI  and body surface
area were 24.2 ± 3.8 kg/m2 and 1.85 ± 0.19 m2, respectively. The
440 T. Fujino et al. / Journal of Cardi
Table  1
Characteristics of younger atrial ﬁbrillation patients.
Baseline n = 95
Age (years) 35.8 ± 4.0
Gender, male/female 85/10
Body mass index (kg/m2) 24.2 ± 3.8
Body surface area (m2) 1.85 ± 0.19
Types of atrial ﬁbrillation; paroxysmal/persistent 64/31
Presence of organic cardiac diseases (%) 8 (8.4)
Hypertension (%) 14 (14.7)
Free thyroxin (ng/dL) 2.91 ± 0.57
Free  triiodothyronine (pg/mL) 1.20 ± 0.30
Thyroid stimulating hormone (mU/L) 1.34 ± 0.58
Duration of atrial ﬁbrillation (month) 33.0 [12.5–60.0]
No.  of ineffective antiarrhythmic drugs 1.62 ± 1.31
0/1/2/≥3  drugs 14/41/21/19
Electrical cardioversion (%) 27 (28.4)
Left ventricular ejection fraction (%) 61.4 ± 9.4
Left  atrial diameter (mm)  37.5 ± 6.7
Left  atrial length (mm)  53.6 ± 6.9
Left  atrial appendage emptying velocity (cm/s) 73.8 ± 29.9
CHADS2 score (points) 0.35 ± 0.70
0/1/≥2  points 71/18/6
Brain natriuretic peptide (pg/ml) 20.8 [9.3–58.3]
No.  of ablation sessions 1.34 ± 0.58
1/2/3 sessions 68/22/5
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Montinuous data were expressed as means ± standard deviation or medians [25–75%
alue].
edian duration (25–75% value) of AF was 33 (12.5–60.0) months,
ncluding both paroxysmal and persistent AF.
The mean left ventricular ejection fraction was 61.4 ± 9.4%. The
ean LA diameter and length determined by echocardiography
ere 37.5 ± 6.7 and 53.6 ± 6.9 mm,  respectively. The LA appendage
ow velocity determined by transesophageal echocardiography
as 73.8 ± 29.9 cm/s; it was measured during sinus rhythm in 68
72%) patients and during AF in the remaining patients.
The CHADS2 score was low in this study, with an average score of
.35 ± 0.70 points. Three-fourths of the patients scored zero points.
The median (25–75%) value of brain natriuretic peptide level
as 20.8 (9.3–58.3) pg/ml.
F ablation outcome and procedural complications
At the ﬁrst session, PVI with bidirectional conduction block of
he CTI was successfully done in all 95 patients. Additional LA lin-
ar ablation and CFAE ablation were performed in 13 (13.7%) and
4 (14.7%) patients, respectively. After the ﬁrst session, 27 (28.4%)
atients had a recurrence and underwent a repeat ablation. Eventu-
lly, we performed a total of 127 sessions for eliminating AF. In this
able 2
omparison of the patient characteristics between the successful and unsuccessful group
Baseline Successful (n =
Age (years) 35.8 ± 3.8 
Gender, male/female 76/10 
Body mass index (kg/m2) 24.5 ± 3.7 
Body surface area (m2) 1.86 ± 0.19 
Presence of organic cardiac diseases, yes/no 7/79 
Hypertension, yes/no 14/72 
Type of atrial ﬁbrillation; paroxysmal/persistent 61/25 
Duration of atrial ﬁbrillation (month) 32.0 [12.0–60
Ineffective antiarrhythmic drugs, 0/1/≥2 13/38/35 
Left ventricular ejection fraction (%) 61.8 ± 8.8 
Left atrial diameter (mm)  37.5 ± 5.9 
Left atrial length (mm)  53.9 ± 6.7 
Left atrial appendage emptying velocity (cm/s) 74.0 ± 28.9 
CHADS2 score, 0/1/≥2 63/17/6 
Brain natriuretic peptide (pg/mL) 19.8 [9.4–58.7
ontinuous data were expressed as means ± standard deviation or medians [25–75% v
ann–Whitney test.3)ology 63 (2014) 438–443
study, we  mainly used an 8-mm-tip nonirrigated ablation catheter;
it was  in 108 (85.0%) sessions and alternatively used a 3.5-mm
irrigated tip ablation catheter in 19 (15.0%) sessions. The success-
ful outcomes of ablation did not differ between the two ablation
catheters (p = 0.617).
During the follow-up of 40 [27.8–49.6] months, sinus rhythm
was maintained in 86 patients (90.5%) without any AADs (paroxys-
mal  AF, 95%; persistent AF, 94%; and long-standing persistent AF,
57%), but not in the remaining 9 patients (9.5%).
Major complications occurred in only 2 patients (1.6%).
Cardiac tamponade was  observed in 1 patient (0.8%), and it
was treated uneventfully with percutaneous pericardiocentesis.
Another patient (0.8%) developed a phrenic nerve injury, which
recovered within a month. In 3 patients (3.2%) with persistent
AF, AF developed AT after ablations; however, this prevalence was
less than that in previous studies [11,12]. With additional sessions,
these ATs were eventually eliminated using CARTO. In this study,
such a navigation system was  used only in this type of case.
Supplementary study in elderly patients
In the same study period (i.e. from February 2007 to September
2010), we  performed catheter ablation procedures in 106 (5.3%)
elderly patients aged over 75 years. We  evaluated an associa-
tion between BMI  and ablation outcome in this population. Sinus
rhythm was maintained in 90 (84.9%) patients without any AADs
during follow-up. The success rate was  slightly low compared
to that of younger patients (90.5%; p = 0.228). Univariate logistic
regression analysis revealed that a low BMI  was not associated with
an unsuccessful ablation outcome (p = 0.943).
Comparison between successful and unsuccessful patients
Table 2 shows a comparison between patients with successful
and those with unsuccessful ablation outcomes. The BMI  sig-
niﬁcantly differed between the 2 groups. Unsuccessful patients
underwent more sessions than successful patents (1.3 ± 0.5 vs.
1.8 ± 0.8, p = 0.015). Regarding the thyroid function, no signiﬁcant
differences were observed between the successful and unsuccessful
patients. One patient had hyperthyroidism, but the hyperthy-
roidism in this patient had been restored to a euthyroid state by
at least 2 months before the ablation.Univariate logistic regression analyses revealed that BMI, AF
duration, persistent AF, and left ventricular ejection fraction were
signiﬁcant predictors of AF recurrence after a ﬁnal ablation proce-
dure (p = 0.012, p = 0.026, p = 0.034, p = 0.028, respectively; Table 3).
s.
 86) Unsuccessful (n = 9) p value
35.2 ± 6.0 0.6721)
9/0 0.5902)
21.1 ± 3.2 <0.011)
1.75 ± 0.16 0.0911)
1/8 0.5642)
0/9 0.3482)
3/6 0.0552)
.0] 36.0 [21.0–96.0] 0.2003)
1/3/5 0.5343)
57.3 ± 14.4 0.1751)
37.8 ± 13.0 0.8911)
51.3 ± 8.6 0.2901)
71.7 ± 40.4 0.8281)
8/1/0 0.3473)
] 44.5 [7.6–50.6] 0.5063)
alue]. p values were determined by an unpaired t test,1) Fisher’s exact test,2) or
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Table  3
Clinical factors associated with an unsuccessful atrial ﬁbrillation ablation procedure determined by logistic regression analyses.
Variables Univariate odds ratio (95% CI) p value Multivariate odds ratio (95% CI) p value
BMI  < 22 kg/m2 6.60 (1.51–28.80) 0.012 7.33 (1.34–40.08) 0.022
Persistent AF 4.88 (1.13–21.05) 0.034 5.20 (0.88–30.71) 0.069
Duration of AF (per month) 1.01 (1.00–1.03) 0.026 1.02 (1.00–1.03) 0.029
LVEF  < 60% 5.17 (1.20–22.33) 0.028 4.25 (0.72–24.97) 0.110
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0he 2 value of the multivariate logistic model was  5.098, and p = 0.648 as determ
ndex;  AF, atrial ﬁbrillation; LVEF, left ventricular ejection fraction.
o test which predictor is most associated with unsuccessful abla-
ion outcomes, we performed a multivariate logistic regression
nalysis. The results showed that BMI  had the most signiﬁcant
alue, with an odds ratio of 7.33 [95% conﬁdence interval (95% CI),
.34–40.08; p = 0.022].
The ROC curve of BMI  as a signiﬁcant predictor of successful
blations showed an AUC of 0.773 (95% CI, 0.591–0.956; p = 0.007).
he cutoff value of 22.1 kg/m2 (Fig. 1, arrow) had a speciﬁcity of
7.8% and a sensitivity of 75.6% in predicting successful ablations.
he positive and negative predictive values of 22.1 kg/m2 were
5.6% and 22.2%, respectively.
iscussion
ain ﬁndings
The main ﬁndings of the present study were as follows. First,
atheter ablation achieved a successful outcome of 90.5% without
ny AADs in symptomatic younger AF patients (deﬁned as <40 years
ld). Second, a multivariate logistic regression analysis showed that
 low BMI  was associated with an unsuccessful ablation outcome.
revalence of AF in younger patients
Although there was one report on patients older than 45 years
hat focused on AF ablation [13], there were no detailed data on the
revalence of AF in younger patients who underwent a catheter
blation procedure. In this study, 95 of 1983 patients (4.8%) were
40 years old. Thus, the patient population under the age of 40 years
hat underwent AF ablation procedures is very few.
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ig. 1. Receiver operating curve of body weight index for an unsuccessful atrial
brillation ablation procedure. The area under the curve was  0.773 (95% CI,
.591–0.956; p = 0.007), and the cut-point value was 22.1 kg/m2.by the Hosmer–Lemeshow test. CI indicates conﬁdence interval; BMI, body mass
The outcome of AF ablation in younger AF patients
In general, the success rate of ablation in younger AF patients
was considered to be high compared to that in elderly AF patients.
In fact, this study supports such a consideration (90.5% vs. 84.9%).
Several factors such as shorter AF duration [14–16], smaller LA
dimension [17–19], and the presence of structural heart disease
may  contribute to the predominance of ablation in general AF
patients.
Interestingly, the duration of AF, the LA diameter, and the pres-
ence of structural heart disease were not predictive of successful AF
ablations in this study with younger patients because these factors
are not conspicuous in younger patients. In addition, there was  no
signiﬁcant difference between the use of an 8-mm-tip nonirrigated
ablation catheter and a 3.5-mm irrigated tip ablation catheter.
In this study, the LA appendage ﬂow velocity determined by
transesophageal echocardiography was relatively better than in the
general population [20]. For this reason, it was mostly measured
during sinus rhythm and was  age-dependent [21,22].
As regards complications, a previous study reported that there
were no major complications out of 309 procedures in younger
patients deﬁned as <45 years old [12]. Similarly, our complication
rate was also low (1.6%), similar to that in the previous study. There-
fore, we recommend the use of ablation therapy even for younger
AF patients, on the basis of the results of this study.
Relation between body size and the outcome of AF ablation
BMI  < 22.1 kg/m2 (a slim physique) had a tendency to be difﬁ-
cult to treat leading to unsuccessful ablation outcome. It has been
reported that patients with a large physique have an increased LA
diameter/volume with PV stretching [23], and AF may  occur eas-
ily. However, the present study showed that the LA diameter was
not related to the ablation success rate. Therefore, we should think
about other mechanisms.
In this study, all unsuccessful patients had multiple non-PV
AF foci. The mechanism of focal ﬁrings in the atrium is generally
associated with autonomic nerve activity, particularly increased
sympathetic nerve activity [24,25]. As shown in numerous reports,
slender patients have higher autonomic nerve activity than obese
patients. Bray [26] reported that obesity causes loss of the auto-
nomic nervous system. In other words, losing weight is associated
with increased autonomic nervous system activity. It may  be more
signiﬁcant in younger patients than elderly patients [27,28]. In
fact, an association between a low BMI  and unsuccessful ablation
outcome was not observed in elderly patients, as shown in a supple-
mentary result. That could be one of the reasons that a low BMI  had
the most signiﬁcant association with unsuccessful outcomes. Local
electrical burst stimulation testing or ganglionated plexi (GP) abla-
tion procedure supports our idea (i.e. a strong association between
a low BMI  and unsuccessful outcomes), while we  did not evaluate
such data in this study.
Concerning why  multiple foci could not be eliminated in slen-
der young patients using conventional AF ablation methods, we had
the following speculations. Slender, young AF patients have many
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[42 T. Fujino et al. / Journal of
ore foci ﬁring in the atrium. That means the foci may  not only
e from the left atrium around PVs, but also from other left atrial
egions such as the left appendage or from the right atrium includ-
ng superior or inferior vena cava and coronary sinus oriﬁce region.
nfortunately, we did not evaluate all foci with atrial ﬁring in the
atients who underwent unsuccessful ablation procedures.
Previous studies have demonstrated that the favorable effects
f obesity, termed the “obesity paradox,” are also seen in patients
ith other cardiovascular diseases, such as congestive heart fail-
re, hypertension, and coronary heart disease [29–32]. The patients
ith obesity had a better prognosis than patients with weight loss.
hese studies also support our observations.
Measurements of the autonomic imbalance markers could
upport our results. In this study population, we  assessed the
utonomic imbalance markers such as the heart rate variability.
he autonomic markers are generally analyzed using the normal-
o-normal beat intervals recorded on 24-h Holter monitoring. As
hown in a previous study [33], it is difﬁcult to measure the
ow frequency (LF) and high frequency (HF) components that are
arameters of the heart rate variability analysis. Miyakoshi et al.
33] demonstrated that the data could be analyzed in only half
f the patients with paroxysmal AF. In this study, persistent AF
atients were included in addition to paroxysmal AF patients. Thus,
e could not assess how the changes in the autonomic balance
efore and after the ablation differed between the slender and
bese patients in the present study.
tudy limitations
This study has some potential limitations. First, it was a retro-
pective and observational study that did not compare the results
ith those in patients > 40 years old. Second, this study had a
mall sample size, which might have caused a statistical bias.
evertheless, the results were found to be clear and statistically
igniﬁcant. Third, the judgment of successful or unsuccessful out-
ome of catheter ablation may  depend on patients’ own  selection to
on-pharmacological therapeutic strategy because we performed
he second or third sessions of ablation according to patients’
esires. Fourth, the reaction to pharmacotherapy including auto-
omic blocking agents such as beta-blockers was not assessed in
his AF patient population and we therefore could not perform a
omparison between the slender and obese patients.
A change in the body weight of AF patients may  modify the AF
ecurrence rate. However, we cannot have answers to this hypothe-
is because a gain of body weight in slender young patients or a loss
f body weight in obese elderly patients is fundamentally difﬁcult
n this type of short-term clinical study.
onclusions
In symptomatic younger AF patients, the success rate of AF abla-
ion is higher than in nonspeciﬁc populations. This study conﬁrms
hat BMI  of <22 kg/m2 was the most signiﬁcant factor for an unsuc-
essful AF ablation procedure.
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